Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical’s Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-13

首程控股(0697.HK)抽取88位幸運觀眾現場觀賽 深度參與世界人形機器人運動會

香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 備受全球科技界矚目的世界人形機器人運動會將於8月14日在北京國家速滑館正式揭幕，這場持續至8月17日的科技盛宴，將成為展示全球人形機器人技術最高水平的重要窗口。作為全球首個以人形機器人為核心參賽主體的大型綜合性賽事，本屆運動會設置了極具看點的多元競賽項目。來自世界各地的超百支頂尖機器人戰隊，將在跑步、足球、街舞、武術、工廠搬運、酒店服務等項目中同場競技，全面展示人形機器人在不同領域的應用潛力。這背後不僅是技術的較量，更是對機器人適應複雜環境、完成精細任務能力的全方位檢驗，每一項比賽都凝聚着人工智慧、機械工程等多學科的技術突破。一、首程控股多維度深度參與在本屆運動會中，首程控股同時扮演資本推動者、場景驗證者及生態運營者的三重角色。依託管理的北京機器人產業發展投資基金及多支產業基金，首程已系統投資布局數十家高成長機器人企業，涵蓋從核心零部件到整機集成、從底層算法到場景應用的全產業鏈。此次亮相的被投企業包括：宇樹科技（Unitree Robotics）、銀河通用（Galbot）、星海圖（Galaxea-AI）、松延動力（Noetix Robotics）、加速進化（Booster Robotics）及自變量機器人（X Square Robot）等，分別在足球、田徑、格鬥、舞蹈、場景賽等核心項目中擔綱主力。二、首程機器人科技體驗店打造沉浸式產業櫥窗運動會期間，位於國家速滑館內的首程機器人科技體驗店同步開放，集中展示50餘家企業近200款產品，涵蓋智慧家居、教育、智能穿戴、娛樂休閒等多個場景。觀眾不僅可近距離體驗人形機器人、智能家電、AI娛樂設備等前沿產品，亦可現場購買，實現「發布-測試-銷售-服務」的消費閉環。該舉措與首程於2025年啟動的全球「機器人綜合體驗店」招募計劃一脈相承，並將為未來在融石廣場等地開設的長期體驗店積累場景與營運經驗。首程控股董事會主席趙天旸表示，機器人市場規模未來將超越汽車行業，中國必將誕生百億美元市值的機器人企業。通過運動會這一「產業櫥窗」，首程不僅展示被投企業的技術實力，更在真實環境中驗證其商業化潛力，加速技術從「實驗室走向市場」的進程。三、租賃公司保障賽事落地為保障賽事前期訓練與正式比賽，北京機器人租賃公司集中交付了100台賽事指定設備，包括82台Booster Robotics足球賽本體、10台Noetix Robotics田徑機器人及8台Galaxea-AI場景賽機器人。全部設備已進駐國家速滑館，重點服務於足球、田徑及場景賽的訓練需求，並由租賃公司與廠商技術團隊聯合駐場提供全流程技術支持，實現「即交付、即服務」的產業響應。觀賽互動福利為感謝市場長期支持，首程控股將抽籤選出88位幸運觀眾親臨現場，見證這場全球頂尖科技的競技舞台。報名截止時間：2025年8月14日（北京時間）上午9:00抽籤時間：2025年8月14日下午3點前公佈，受邀者將收到電郵或短信通知參與方式：1.通過鏈接填寫報名信息：https://www.wjx.cn/vm/mfW64yI.aspx#2.關注「首程控股」官方微信公眾號，後台留言「機器人運動會」，按彈出鏈接填寫報名信息。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-13

康基醫療收到由董事長鍾鳴、TPG及卡塔爾投資局(QIA)牽頭財團提出之私有化要約 助力公司實現長遠願景

康基醫療控股有限公司與Knight Bidco Limited今日聯合宣佈，擬通過協議安排（"建議交易"）對公司進行私有化。康基醫療控股有限公司私有化要約：每股9.25港元的註銷價較股份於截至未受干擾日期（即2025年6月30日）之收盤價溢價約21.7%，較股份於截至未受干擾日期（包括該日）止360個交易日在聯交所所報的平均收盤價溢價約47.3%，且超過了2022年以來於聯交所錄得之最高收盤價。本次私有化擬以協議安排實施，要約人及其一致行動人士合共持有公司74.75%之股份；已獲得一家機構股東作出的不可撤銷承諾，將投票支持該私有化方案。該方案為股東提供明確機會，使其能夠於康基醫療控股有限公司之股份持續面臨交易價格壓力及流動性受限之際，變現其於公司之權益。香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 2025年8月12日，康基醫療控股有限公司（「康基醫療」或「公司」，股份代號：9997.HK）與KNIGHT BIDCO LIMITED「要約人」今日聯合宣佈，雙方擬以協議安排的方式對公司進行私有化，以期公司能夠專注於長期戰略決策，包括研發長期投入及運營升級。待該方案完成後，公司將成為要約人的全資附屬公司，而公司股份於聯交所的上市地位將被撤銷。要約人由以下成員組成的財團全資持有：鍾先生與申屠女士（創始人）、TPG實體、NewQuest V基金及Al-Rayyan Holding。交易理據鑒於股票的交易價格持續承壓且流動性長期不足，公司從股票市場籌集資金的能力受到嚴重限制。除此之外，本公司為維持上市地位須承擔行政、合規及其他與上市相關之成本及開支，故維持上市地位之裨益有限。由於國內市場競爭加劇及持續之監管不確定性，為實現可持續增長，公司之長期策略需進行重大投資，此舉可能對短期財務表現造成壓力。預計需將額外資源分配至以下領域：銷售與市場推廣、研發及商業化投資，以及中國境外之市場擴張。鑒於維持上市地位之裨益有限，且涉及相關上市成本，康基醫療繼續維持上市地位之必要性已顯著降低。此外，該方案之實施將緩解公司短期財務表現所受壓力，從而更專注於戰略目標之推進。公司預期需要配置更多資源，以保障其未來可持續發展。此外，該方案為少數股東提供具吸引力之機會，使其能在市場波動、行業及宏觀不確定性，以及股份流動性有限之情況下，實現可觀回報。KNIGHT BIDCO LIMITED提出的私有化方案為康基醫療及其股東提供了及時有效的解決方案，提議將康基醫療私有化的方案將：(a) 降低康基醫療的行政、合規及其他上市相關成本；(b) 緩解康基醫療面臨的短期業績指標壓力，使康基醫療能夠專注於長遠戰略決策（例如可能導致短期虧損的長期研發投入及運營升級）；以及(c) 為現有股東提供明確保障，使其能以顯著高於未受干擾股價之溢價，實現於康基醫療之權益變現。綜上所述，要約方認為私有化交易能為全體股東提供即時且最具吸引力價值的戰略選擇，同時可規避不確定市場環境帶來的風險。交易方案概述本次私有化方案設定的股份註銷價格為每股9.25港元，按股權價值計算對公司估值約為14億美元。[1]要約方已明確表示，註銷價格為最終定價且後續不會上調。該註銷價格體現以下考量：較股份於未受干擾日期（即2025年6月30日）在聯交所所報收盤價溢價約21.7%。較股份於截至未受干擾日期（包括該日）止360個交易日在聯交所所報的平均收盤價溢價約47.3%。以及截至未受干擾日期（包括該日）止於聯交所所報之股份價格的過去52週最低收盤價（5.01港幣）溢價約84.6%。此外，在較長的過往期間內，註銷價格超過了股份自2022年以來的最高收盤價（8.66港幣）。本次註銷價格的確定已綜合考量下列因素（包括但不限於），股份於聯交所的近期及歷史交易價格，公司公開披露的財務資訊，及參照近年來香港市場類似私有化交易案例。該方案的實施受限於所有先決條件於2026年1月31日（先決條件最後截止日期）或之前達成，並在2026年4月30日（最後截止日期）之前滿足條件。公司將委任獨立財務顧問（"IFA"）向為方案目的而設立的獨立董事委員會（"獨立董事委員會"）提供意見，以便就方案向股東作出推薦建議。方案的詳情，包括獨立董事委員會的最終推薦意見及獨立財務顧問的意見函，將載入計劃文件，並預期在切實可行的情況下儘快寄發給股東。協議安排會議協議安排會議的具體細節將載於計劃文件，該文件預計將於適當時候寄發予股東。本次交易尚需滿足《聯合》公告所列的多項先決條件及條件，包括但不限於監管批准、股東批准及其他法定合規要求。不可撤銷承諾本公司已獲得一名機構股東作出的不可撤銷承諾，將就該項提案投贊成票。詳情請參閱《聯合公告》。康基醫療已於2025年7月18日上午9時正起於聯交所暫停買賣，以待刊發本公告。公司已向聯交所申請股份自2025年8月13日上午9點起恢復買賣。摩根大通擔任要約方獨家財務顧問關於康基醫療控股有限公司康基醫療控股有限公司創立於2004年，總部位於中國浙江省杭州市，於2020年6月在香港聯合交易所主板上市，股票代碼9997.HK。公司專注于設計、開發、生產和銷售微創外科手術器械及配套耗材(「MISIA」)，秉持著「為醫生提供優質產品和服務，致力於人類健康事業」為使命，通過豐富的產品組合為婦產科、普外科、泌尿外科和胸外科等臨床科室的微創外科手術提供一站式解決方案，並致力於發展為一個立足中國，輻射全球的國際化微創外科手術器械及配套耗材平台。關於Knight Bidco Limited要約人、MidCo 及TopCo均為於開曼群島新註冊成立的有限公司及僅為實施該建議而成立的投資控股公司。於本公告日期，要約人由MidCo全資擁有，而MidCo由TopCo全資擁有。於本公告日期，TopCo由財團成員持有，其中Fortune Spring ZM、Fortune Spring YG、TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding分別持有約25.53%、約14.47%、約24.38%、約5.01%、約5.69%、約4.56%及約20.36%。截至本公告發布之日，除聯合公告中「公司的股權架構」一節所披露外，TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding 均非股東。康基醫療現由鍾鳴先生及其配偶申屠女士共同控制，二人合計持有康基醫療52.98%股份。待私有化完成後，鍾氏夫婦將通過"Fortune Spring ZM"與"Fortune Spring YG"繼續持有要約方最終控股公司（TopCo）40.00%股權，並保持第一大股東地位。更多細節詳見《聯合公告》。各創始人實體均為英屬維爾京群島註冊成立的商業公司。Knight Success為一家於新加坡新註冊成立的有限公司及且為一家投資控股公司。Keyhole為一家於開曼群島註冊成立之獲豁免有限公司及投資控股公司。TPG Asia VII為一家於新加坡註冊成立的有限公司。Knight Success 及Keyhole均由TPG Asia VII全資擁有或控制，而後者由TPG Asia GenPar VII Advisors, Inc.控制，並最終由納斯達克上市的特拉華州公司TPG Inc. 控制。TPG是一家全球領先的另類資產管理公司，成立於1992 年，截至2025年6月30日年管理的資產超過2,690億美元。多年來，TPG一直致力於投資變革、增長與創新，旨在為投資者構建多元化的產品與策略，同時藉由貫徹紀律及卓越的營運管理，提升投資策略與投資組合的整體表現。NewQuest V為一家於新加坡註冊成立的有限公司及投資控股公司。NewQuest V由NewQuest Asia Fund V, L.P. 全資擁有，而後者由NewQuest Asia Fund V GP Ltd.控制，並最終由納斯達克上市的特拉華州公司TPG Inc.控制。NewQuest成立於2011年，是亞洲領先的二級私募股權平台之一，擁有亞洲最有經驗的二級團隊，分佈於五個辦事處。自成立以來，NewQuest 一直專注於與普通合夥人合作，創建定制的解決方案，以滿足私募資產持有人及其利益相關者的流動性和其他戰略需求。從2018年建立的戰略合作夥伴關係開始，NewQuest 於2022 年1月成為TPG的全資附屬公司。Al-Rayyan Holding為一家根據卡塔爾金融中心管理局的規定於2012年在卡塔爾成立的有限責任公司，且為卡塔爾主權財富基金卡塔爾投資局全資擁有的間接附屬公司。成立於2005年的卡塔爾投資局旨在投資和管理國家儲備基金。卡塔爾投資局為全球最大、最活躍的主權財富基金之一。卡塔爾投資局投資於廣泛的資產類別及地區，並與世界各地的領先機構合作，建立具有長期前景的全球化及多元化投資組合。於本公告日期，Al-Rayyan Holding 及其一致行方（與Al-Rayyan Holding 單獨或被視為與該財團一致行事的各方除外）均不持有任何股份。如有垂詢，敬請聯繫：康基醫療控股有限公司要約人傳媒聯絡：皓天財經集團有限公司Angie Li & Jason Lai電話：(852) 6150 8598 / (852) 9798 0715電郵：po@wsfg.hk傳媒聯絡: 博然思維Kay Lau+852 6021 7009Tong Li+86 134 8872 6729電郵：TeamKnight@brunswickgroup.com[1] 以每股9.25港币的注销价格、1,207,994,000股流通股，以及7.85的美元兑港币汇率计算免責聲明：本新聞稿中使用的所有未另行定義的大寫術語，其含義均以2025 年 8 月 12日 發佈的《聯合公告》中的釋義為准。本新聞稿須與《聯合公告》全文一併閱讀，公告副本可在以下鏈接查閱。https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201339_c.pdf Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-13

五礦資源公佈2025年中期業績 強勁銅產量驅動利潤、收益和現金流增長

香港，2025年8月12日 - (亞太商訊 via SeaPRwire.com) - 五礦資源有限公司（「MMG」；股份代號：1208）今日發佈二零二五年中期業績，公司除稅後淨利潤達566.3百萬美元，較二零二四年上半年的除稅後淨利潤79.5百萬美元增長逾600%。這一強勁利潤提升主要得益於旗下三座銅礦的銅產量均有所增長，銅、金、銀、鋅的市場價格上揚，以及Las Bambas因銅產量提升而實現單位成本下降。MMG行政總裁趙晶表示：「今年上半年，MMG的業務實現了卓越的經營和財務表現。此成果充分展現出公司資產組合的優勢、團隊的卓越能力以及對戰略規劃的堅定執行力。」值得關注的是，二零二五年上半年，MMG的安全績效有所改善，每百萬工作小時可記錄總工傷事故頻率（TRIF）為1.81，低於二零二四年全年的2.06。二零二五年上半年具有能量交換的重大事件頻率（SEEEF）為每百萬工作小時0.78，與二零二四年持平。運營方面，公司旗下三座銅礦山的銅銷量與產量均顯著提升，其中Las Bambas表現強勁，Khoemacau和Kinsevere亦處於爬坡階段。澳大利亞兩座礦山雖面臨天氣影響、設備可靠性以及採礦順序導致的品位下降等挑戰，鋅產量仍保持穩定。要點：上半年的EBITDA及EBIT均創下歷史新高，其中EBITDA達1,539.9百萬美元，較二零二四年上半年增長98%，而EBIT總計1,058.8百萬美元，較去年同期增長240%。除稅後淨利潤達566.3百萬美元，包括本公司權益持有人應佔利潤340.0百萬美元。經營活動現金流淨額較二零二四年上半年增長130%，總額達1,185.0百萬美元。這主要受銅銷售量增加及商品價格上漲推動。資產負債持續改善，自Las Bambas收購以來，債務淨額及槓桿率均創下歷史新低。其中，債務淨額自二零二四年底以來減少903.3百萬美元，主要得益於強勁的運營現金流及提前償還Khoemacau合營公司集團500百萬美元的貸款。二零二五年上半年，槓桿率從41%下降至33%。二零二五年上半年，應付銅銷售總量達237,651噸，創二零一八年以来歷史新高。Las Bambas二零二五年上半年銅精礦含銅的產量達210,637噸，較二零二四年同期增長67%。EBITDA創下歷史新高，達1,310.5百萬美元，較二零二四年上半年增長122%。趙晶補充道：「MMG的資產負債表達至十年來最穩健水平--受惠於盈利提升和現金流創造帶動的債務削減。我們躋身全球十大銅生產商的目標觸手可及，透過卓越的運營表現、審慎的資本分配，以及對負責任採礦的持續承諾，我們已為實現這一目標奠定良好基礎。」二零二五年的生產指引維持不變，銅總產量最高可達522,000噸，鋅產量最高可達240,000噸。如果運營環境穩定且無外部干擾，Las Bambas今年有望實現高達400,000噸的銅產量。MMG正致力達成成本目標，Las Bambas和Rosebery已下調C1成本區間，以反映副產品收益改善及強勁的市場條件。本公司正努力完成近期對巴西鎳業的收購，並對公司的長期資產組合及增長前景充滿信心。MMG將持續推動運營所在社區的發展，促進當地經濟與就業，並為全球可持續未來供應所需的關鍵礦物。點擊查看完整的中期業績報告，觀看行政總裁致辭視頻以及下載公司圖片。關於MMGMMG成立於二零零九年，其願景是為低碳未來打造國際領先的礦業公司。公司總部位於澳大利亞墨爾本和中國北京，並在香港聯合交易所上市（聯交所：1208）。MMG的资产組合涵蓋銅、鋅和鈷的生產，並即將拓展至鎳領域。這些金屬資源對全球脫碳和電氣化目標的實現至關重要。目前，公司的運營業務分佈澳大利亞、博茨瓦納、剛果民主共和國及拉丁美洲。更多信息請點擊此處。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-13

GEON高效能解決方案連續第二年榮獲全球「最佳職場」認證

俄亥俄州西湖, 2025年8月12日 - (亞太商訊 via SeaPRwire.com) - 全球領先的高性能聚合物解決方案配方、研發和製造企業GEON®高性能解決方案公司今日宣布，其位於美國、加拿大、墨西哥和中國的分支機構已獲得Great Place To Work®（GPTW，「最佳職場」）認證。自2021年與GPTW合作以來，GEON一直秉持著文化與可持續發展的願景，力爭每年都獲得這一殊榮。通過 GPTW 認證GEON獲美國、加拿大、墨西哥和中國「最佳職場」認證。GPTW要求員工對自身體驗、職場文化以及領導行為進行量化評估和基準比較，這些因素已被證明能夠帶來市場領先的營收、員工留任率的提升以及創新能力的增強。「我們非常高興能在公司運營的四個國家連續兩年獲得『最佳職場』認可。『最佳職場』的評選是與全球頂尖僱主進行比較的，這證明了我們在追求卓越企業文化的道路上正走在正確的方向上。」GEON首席執行官特蕾西‧加里森（Tracy Garrison）表示，「我們相信，市場上的領導者也必須是職場上的領導者。為此，我們在全球各地的運營中都致力於營造積極的工作文化，同時努力在仍需提升的領域不斷進步。」GEON獲得了79%的員工敬業度評分，比典型公司高出20%以上。在美國、加拿大和中國，GEON的評分較去年有所提升，在墨西哥則保持穩定。美國的調查涵蓋了GEON的所有員工，包括 GEON於2025年1月收購的Foster, LLC 的員工。根據 Great Place To Work research 的研究，在獲得「最佳職場」認證的企業中，求職者找到優秀上司的可能性高出4.5倍。此外，在通過認證的企業工作，員工期待上班的可能性高出93%，並且獲得公平薪酬和公平晉升機會的可能性是普通企業的兩倍。「正如數據所示，獲得 GPTW 認證不僅反映了我們的企業文化，還直接影響了我們留住那些每天都期待來上班的優秀員工的能力。」GEON 首席人力資源官傑羅姆‧貝格里（Jerome Beguerie）表示，「這對我們的客戶以及他們與我們合作的體驗都有直接影響。」關於 GEON 高性能解決方案GEON® 高性能解決方案是聚合物混配解決方案領域的領先創新者，服務於包括建築與基礎設施、消費品、工業、交通運輸以及電力與通訊等在內的廣泛市場。通過收購 Foster, LLC，GEON 進一步增強了在高速增長的醫療保健和醫療器械行業的參與度，並在高度適應性的乙烯基、聚烯烴和工程樹脂技術組合基礎上，拓展了全方位合同製造業務。GEON 在全球擁有約 1,200 名員工和 15 家世界一流的製造工廠，總部位於俄亥俄州西湖市。了解更多資訊，請訪問 http://www.geon.com 。GEON 是 SK Capital Partners 投資組合中的一家公司。關於 SK CapitalSK Capital 是一家具有變革力的私募投資公司，專注於特種材料、配料以及生命科學領域。公司致力於打造具有韌性、可持續性和增長潛力的企業，從而創造可觀的長期價值。SK Capital 力求利用其在行業、營運和投資方面的經驗，尋找機會將企業轉型為具有更高績效、更優戰略定位、更強增長與盈利能力且營運風險更低的組織。截至 2024 年 12 月 31 日，SK Capital 管理的資產總額約為 100 億美元。更多資訊請訪問 http://www.skcapitalpartners.com 。聯絡資訊Renita AndersonVice President, Marketing & Business Developmentrenita.anderson@geon.com678-772-8953來源: GEON Performance Solutions Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-13

Formerra 成為 Syensqo PVDF 的北美區經銷商

伊利諾州羅密維爾, 2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 作為高性能材料分銷領域的領導者，Formerra 已與 Syensqo 簽署協議，負責在北美地區分銷其 Solef® 聚偏二氟乙烯（PVDF）材料。該協議擴大了這種關鍵材料的供應範圍，該材料以兼具耐化學性與柔韌性而聞名。Solef® PVDF 加入了 Formerra 日益壯大的高性能材料產品組合，旨在推動產品開發與創新。「透過這項新協議，Formerra 將能夠為多個市場的客戶提供所需材料，以滿足嚴苛的應用需求。」Formerra 業務開發經理 Bob Long 表示：「此外，這也進一步強化了我們的承諾，即為在複雜的性能與法規挑戰中前行的客戶，提供無與倫比的供應渠道、應用支援以及先進材料。」PVDF 因其優異的耐化學性與耐熱性，被定位於性能金字塔的頂端附近。其固有的柔韌性，更進一步提升了其在化學加工、醫療保健及汽車等行業嚴苛應用中的適用性。其主要特性*包括：耐熱性：可在高達 150 °C（302 °F）的環境中持續使用，於室溫下可承受高達 139 bar（2,017 psi）的爆破壓力化學純度：具超純水耐受性，符合半導體產業 SEMI F-57 規範強度與柔韌性的平衡：抗拉屈服強度可達 55 MPa（8,000 psi），斷裂伸長率可達 100%「我們選擇 Formerra 作為 Solef® PVDF 在北美的經銷合作夥伴，是基於他們在技術與商業領域的廣泛觸及能力。」Syensqo 特用高分子公司美洲區銷售總監（通路合作夥伴、經銷與數位銷售）Rose Catherin 表示：「他們對卓越的承諾，以及在關鍵市場的長期耕耘，使其成為擴大 Solef® PVDF 供應與應用的理想夥伴。」*以 TDS 測量標題：Formerra 成為 Syensqo Solef® PVDF 的北美區經銷商重點資訊：Formerra 是 Syensqo Solef® PVDF 在北美的授權經銷商。該協議涵蓋對多元產業高性能應用的支援。PVDF 具備優異的耐化學性、熱穩定性與柔韌性。Formerra 提供技術指導與供應鏈專業知識，協助材料選擇與應用開發。關於 FormerraFormerra 是領先的工程材料分銷商，將全球頂級聚合物與特種材料製造商與醫療保健、消費品、工業與移動出行等市場的數千家 OEM 與品牌商緊密連結。憑藉技術與商業專業能力，Formerra 提供獨特的產品組合深度、強大的供應鏈實力、深厚的產業知識、卓越的服務、領先的電子商務能力以及創新精神。經驗豐富的 Formerra 團隊協助各行業客戶以全新且更優的方式設計、選擇、加工及開發產品，從而提升性能、生產力、可靠性與永續性。欲了解更多資訊，請造訪 www.formerra.com。媒體聯絡Jackie MorrisFormerra 行銷傳播經理jackie.morris@formerra.com來源: Formerra Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-13

中國利郎公佈二零二五年中期業績

香港，2025年8月12日 - (亞太商訊 via SeaPRwire.com) - 中國利郎有限公司（「中國利郎」或「本公司」，及其附屬公司，統稱「集團」；股份編號：1234）今天公佈其截至二零二五年六月三十日止六個月中期業績。中國利郎主席兼非執行董事王冬星先生說：「二零二五年上半年，國際貿易環境更趨嚴峻復雜。期內，內地消費逐步復甦，但消費者對非必需品的支出仍然謹慎。中國利郎通過差異化品牌矩陣深耕男裝市場，通過精準的產品定位與渠道策略，鎖定目標客群，推出多款『利郎LILANZ』及『利郎LESS IS MORE』品牌產品，滿足消費市場需求。此外，集團積極佈局全域營銷，加強利郎品牌的知名度，提升線上線下渠道銷售效益，以推動整體銷售，提升營運效益。 」截至二零二五年六月三十日止上半年，集團收入同比增加7.9%至人民幣17.3億元。其中，輕商務及其他系列收入大幅上升31.8%，主要由於輕商務在門店和新零售表現良好的帶動。主系列收入輕微下跌0.2%，主要由於集團在山東與重慶推進DTC業務模式帶來的一次性收入扣減所致。毛利率為50.2%，同比上升0.2個百分點，主要由於直營銷售佔比上升提高了平均單價所致。期內權益股東應佔利潤為人民幣2.4億元（二零二四年上半年：人民幣2.8億元），權益股東應佔利潤率為14.0%（二零二四年上半年：17.5%），每股盈利為人民幣20.2分。期內集團保持財政穩健，現金流充足。董事會建議派發中期股息每股11港仙（二零二四年上半年：13港仙）及特別中期股息每股5港仙（二零二四年上半年：5港仙），繼續維持穩定的派息比率。集團積極推進戰略轉型，並落實「多品牌、國際化」發展策略，實現業務持續擴張。「利郎LILANZ」主系列繼續鞏固在傳統男裝市場的競爭優勢，成功提升品牌知名度和擴大市場份額。主系列於去年完成東北地區及江蘇省的分銷及代銷權回購轉制，並於期內向山東全省和重慶市一級分銷商回購經營權，以DTC模式轉型。針對較年輕消費者的「利郎LESS IS MORE」輕商務系列繼續以全直營模式經營。輕商務新增門店主要集中在西南及中南地區。截至二零二五年六月三十日止，主系列門店共2,443家，輕商務門店331家。期內，集團繼續致力優化銷售渠道，按計劃在優質地段開設購物中心店及奧特萊斯店，及通過科技感的視覺設計和年輕化的空間佈局，將「簡約不簡單」的品牌理念具象化呈現，以提升品牌形象及推動銷售。於二零二五年六月三十日，購物商場店增加至957家（二零二四年十二月三十一日933家）；奧特萊斯店則增加至121家（二零二四年十二月三十一日：103家），共有2,774家零售店。集團新零售業務完成戰略轉型，從過往的庫存清理渠道升級為主力新品銷售平台，於期內收入錄得24.6%的顯著增長。集團持續深耕天貓、京東、抖音等成熟銷售平台的同時，拓展了拼多多、微信視頻號、得物等新興渠道，形成多元化線上銷售網絡。集團同時利用小紅書、微博等社交平台，持續輸出高品質內容，強化內容電商佈局，從而深化與消費者的情感聯結，並擴展新的業務機遇。集團「多品牌、國際化」發展戰略方面，萬星威「MUNSINGWEAR」上半年完成交易交割，計劃於下半年開設首批實體店。而集團在馬來西亞組開設首家門店的計劃順利落實，並於五月份試業，實現海外拓展的成功一步。在產品研發及品牌營銷方面，集團致力在面料、工藝和技術上取得突破，實現全產業鏈自主研發，加強品牌的核心競爭優勢。期內，集團創新研發的持久白免燙襯衫、拒水羽絨3.0及耐洗POLO衫在抗皺、快乾、耐洗等功能上取得多項認可，成功帶動銷售增長。為進一步深化品牌年輕化戰略，集團於期內借助明星影響力、文化IP聯動及沉浸式場景營銷，觸達各線城市及不同年齡層消費者。展望二零二五年下半年，縱然中國消費市場發展仍然存在不同挑戰，中國利郎作為行業的領先者，將繼續發揮自身優勢，因應消費市場變化和科技創新發展，推動變革轉型，提升品牌影響力，實現銷售及盈利持續增長。集團在下半年將繼續深化轉型，主系列將持續在東北地區、江蘇省、山東省和重慶市發揮DTC模式的經營優勢，以實現穩健擴張。同時，集團將根據各市場的具體情況適度擴大規模，進一步提升營運表現。針對全直營模式經營的輕商務系列，集團將著力加強發展基礎，維持目前高速發展的勢頭。集團預期DTC模式於下半年充分釋放潛力，為整體銷售增長作出貢獻。另一方面，集團繼續利用銷售渠道改革的優勢，聚焦省會城市及地級市優質購物中心的核心位置開店，並關閉低效店舖，以提升門店效率；同時亦會審慎佈局奧特萊斯店，增加門店數量以加快清理庫存。二零二五年全年淨開店目標為50至100家門店。為實現線上線下同步發展，集團將致力推進新零售業務發展，繼續善用各個平台，以瞄準年輕客戶群並加強品牌滲透。透過多維度增加品牌曝光，目標新貨品銷售佔電商銷售總金額的比重能提高至80%。同時，集團會通過智慧物流園區的持續升級，進一步優化供應鏈回應速度，滿足消費者需求。集團目標於二零二五年實現新零售業務收入增長20%或以上，整體銷售增長目標不少於10%。憑藉在國內的堅實基礎，集團有信心加速實現「多品牌、國際化」發展策略。萬星威「MUNSINGWEAR」作為多品牌策略的重點項目，下半年會繼續聚焦產品開發，滿足新中產階級對個性化、功能性及可持續時尚的需求。海外業務方面，集團下半年將在馬來西亞開設更多門店，進一步開拓馬來西亞的市場，並同時將積極部署把業務計劃擴大至東南亞其他市場。同時，集團將通過與跨界IP的合作，提升品牌知名度。結合精準的社交媒體行銷和會員計劃，集團將進一步增強與消費者的互動，提升顧客黏性，提升市場份額。王冬星主席總結說：「縱然中國消費市場發展仍然充滿挑戰，但中國政府實施多項提振消費措施，集團對零售市道審慎樂觀。『利郎LILANZ』主系列及『利郎LESS IS MORE』輕商務系列實現創新轉型後，各自定位更為清晰，有利集團從產品開發設計、營銷推廣和銷售方面，做到更精準更高效，成為集團長遠增長動力。另一方面，作為可持續發展的堅定踐行者，集團將ESG理念深度融入企業戰略，持續推動綠色創新與社會共贏。集團於期內首次發佈獨立編制的ESG報告《共創美好生活》，並正式成立ESG管理委員會，將ESG治理納入戰略規劃和核心價值觀中，展現集團對長期價值的承諾。期內，利郎的MSCI ESG評級升至BB，躋身國內男裝行業前列。未來，集團將繼續鞏固在國內男裝行業的領導地位，通過靈活的市場策略和持續創新，實現可持續增長，為股東、員工及客戶創造更大價值。」關於中國利郎中國利郎是中國領先的男裝企業之一。作為一家綜合時裝企業，集團設計、採購、生產並以品牌「利郎LILANZ」及「利郎LESS IS MORE」銷售優質男士商務及休閒服裝。其產品主要於遍佈中國31個省、自治區及直轄市的廣闊零售及分銷網絡銷售。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-12

康師傅控股有限公司「產品結構+運營效率」持續優化 聚焦長期主義

香港, 2025年8月12日 - (亞太商訊 via SeaPRwire.com) - 2025年8月11日，康師傅控股有限公司（0322.HK，以下簡稱「公司」，連同其附屬公司「集團」）發佈2025年上半年業績公告。2025年上半年，本集團敏銳把握發展契機，聚焦核心業務的精細化運營，持續優化成本結構與運營效能，扎實推進高質量發展進程，整體經營表現穩健，關鍵財務指標持續向好。截至2025年6月30日止六個月，集團收益同比下降2.7%至400.92億元人民幣。其中，方便面事業收益為134.65億元人民幣，飲品事業收益為263.59億元人民幣。毛利率同比提高1.9個百分點至34.5%，EBITDA同比增長13.0%至54.51億元人民幣。受毛利率同比提高帶動，本公司股東應佔溢利同比提高20.5% 至22.71 億人民幣。財務摘要 截至6月30日止6個月 人民幣千元2025年2024年變動收益40,092,16341,201,208↓ 2.7%毛利率（%）34.5%32.6%↑ 1.9個百分點集團毛利13,815,03513,439,915↑ 2.8%扣除利息、稅項、折舊及攤銷前盈利（EBITDA）5,450,6374,824,605↑ 13.0%本期溢利2,688,3042,235,065↑ 20.3%本公司股東應佔溢利2,271,1161,885,310↑ 20.5%本公司股东应佔经调整溢利*2,111,6041,855,310↑ 12.0%每股溢利（人民幣分） 基本40.3033.46↑ 6.84分 攤薄40.2833.46↑ 6.82分於2025年6月30日之銀行存款及現金（含長期定期存款）為人民幣19,491,373千元，相較2024年12月31日增加人民幣3,488,705千元，淨負債與資本比率為-35.0%。* 本公司股東應佔經調整溢利包括除出售附屬公司産生的收益之一次性交易外之所有本公司股東應佔溢利。2025年上半年，中國經濟在結構性挑戰中保持穩健增長態勢。消費市場呈現多元化特徵，消費者在健康需求與休閒享受、個性化追求與大眾化選擇之間尋求平衡，更加注重產品品質、情感共鳴與差異化體驗。消費行為呈現「高頻次、低單量」特點。即時零售業態快速崛起，興趣電商已成為線上流量的核心入口，折扣店與會員店模式加速擴張，全渠道融合與縣域下沉成為新增量。在此背景下，具備敏銳市場洞察力、能夠圍繞健康化、場景化需求創新產品組合，並通過多渠道深度滲透實現用戶觸達與轉化的企業，將更高效地響應市場需求變化，持續強化用戶粘性，實現高質量發展。2025年上半年，方便面事業的毛利結構持續優化。方便面事業收益為134.65億元人民幣，佔集團總收益33.6%。期內因產品升級調價，方便面毛利率同比提高0.7個百分點至27.8%。由於毛利率同比提高帶動，方便面事業2025年上半年的本公司股東應佔溢利同比提高11.9%至9.51億人民幣。期內，面對消費趨勢日益多元化及渠道變革持續加速的外部環境，方便面事業積極應對挑戰，秉持高質量發展理念，通過優化核心品類結構與創新產品組合實現業務持續增長。通過構建多價位的產品矩陣，全面滿足消費者對即食美味的多樣化需求。在品牌營銷方面，依託知名IP合作與明星代言矩陣，有效深化品牌情感價值傳遞，精准觸達年輕消費群體並建立深度共鳴。渠道策略上，重點發力零食量販、會員店等新興渠道，推出差異化場景產品以精准匹配細分市場需求。作為方便面行業航天技術應用的開拓者，率先將航天技術與標準引入制面工藝，「天選好面」以航天標準重塑品質內核，為消費者帶來值得信賴的卓越體驗。飲品事業堅定貫徹「穩增長調結構」雙輪驅動發展戰略。飲品事業整體收益為263.59億人民幣，佔集團總收益65.7%。期內，因原材料有利與管理效能提升，飲品毛利率同比提高2.5個百分點至37.7%。由於毛利率同比提高，飲品事業2025年上半年本公司股東應佔溢利同比提高19.7%至13.35億人民幣。期內，通過持續優化產品口味創新、包裝升級及工藝改進，不斷提升產品競爭力，夯實核心品類領先地位。同時深化消費者洞察，精准把握市場需求，依託強勁研發實力加速創新產品升級。在營運策略上，積極擁抱渠道多元化趨勢，構建全域營銷體系，強化線上線下協同效能。數字化轉型方面，以 AI 技術為核心加速戰略升級，構建企業級數據中台，賦能業務決策與運營效率，持續鞏固和擴大市場競爭優勢。康師傅行政總裁陳應讓先生表示：「展望2025年下半年，政府將繼續強化促消費擴內需政策組合，居民消費潛力有望得到進一步釋放。在此背景下，本集團堅定貫徹『鞏固、革新、發展』的戰略方針，恪守長期主義發展理念，以消費者需求為立足點，聚焦主營業務深耕細作，致力於實現健康高質量的發展。在產品層面，通過優化產品結構、加大研發投入，構建多層次、高品質的產品矩陣，持續提升產品力與差異化競爭優勢；在品牌建設方面，實施多元化營銷策略，強化與消費者的情感連接，實現品牌聲量與情感價值的雙重提升；在運營管理上，加速數字化轉型進程，重點推進企業級數據中台建設，深化AI技術應用，構建智能運營體系以賦能業務決策；在經營質量方面，持續優化成本結構，提升盈利能力，確保經營態勢穩健發展與業績高質量增長。我們將可持續發展理念融入經營實踐，堅定履行社會責任，敏銳把握市場機遇，致力於實現經濟效益與社會價值的協同發展。我們將與合作夥伴攜手共進，以優質產品服務消費者，以豐厚回報回饋股東，矢志成為政府認可、夥伴信賴、消費者首選的綜合性食品飲料『民族品牌』。」關於康師傅控股有限公司 (0322.HK)康師傅控股有限公司（「本公司」）及其附屬公司（「本集團」）主要在中國從事生產和銷售方便面及飲品。本集團於1992年開始生產方便面，並自1996年起擴大事業至方便食品及飲品；2012年3月，本集團進一步拓展飲料事業範圍，完成與PepsiCo中國飲料事業之戰略聯盟，開始獨家負責制造、灌裝、包裝、銷售及分銷PepsiCo於中國的非酒精飲料。「康師傅」作為中國家喻戶曉的品牌，經過多年的耕耘與積累，深受中國消費者喜愛和支持。如有垂詢，請聯絡：投資者查詢康師傅控股有限公司投資者關係團隊電郵：ir@tingyi.com匯思訊中國有限公司陳敏芝電郵：stephanie.chen@christensencomms.com電話：+852 2117 0861 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-12

Tingyi (Cayman Islands) Holding Corp.: Sustained Optimization of Product Portfolio and Operational Efficiency Drives Long-Term Growth, Gross Margin Reached 34.5% and EBITDA Up 13.0% YoY in H1 2025

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - On August 11, 2025, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its interim results for the six months ended 30 June 2025. In the first half of 2025, the Group remained agile in identifying and capturing growth opportunities, while maintaining a disciplined focus on its core businesses. Continued optimization of cost structures and operational efficiency supported the Group’s commitment to high-quality growth, resulting in stable performance and continued improvement across key financial indicators. For the six months ended on June 30, 2025, the Group’s revenue decreased by 2.7% year-on-year to RMB40.092 billion. Of this, the revenue from Instant Noodles was RMB13.465 billion, while the revenue from Beverages was RMB26.359 billion. Gross margin expanded by 1.9 percentage points year-on-year to 34.5%. EBITDA increased by 13.0% year-on-year to RMB5.451 billion. Driven by the improved gross margin, net profit attributable to owners of the Company increased by 20.5% year-on-year to RMB2.271 billion.Financial Summary For the six months ended 30 June RMB’00020252024ChangeRevenue40,092,16341,201,208↓ 2.7%Gross margin34.5%32.6%↑ 1.9 ppt.Gross profit of the Group13,815,03513,439,915↑ 2.8%EBITDA5,450,6374,824,605↑ 13.0%Profit for the period2,688,3042,235,065↑ 20.3%Profit attributable to owners of the Company2,271,1161,885,310↑ 20.5%Adjusted profit attributable to owners of the Company*2,111,6041,885,310↑ 12.0% Earnings per share (RMB cents) Basic40.3033.46↑ 6.84cents Diluted40.2833.46↑ 6.82centsAs at 30 June 2025, cash at bank and on hand (including long-term time deposits) was RMB19,491.373 million, representing an increase of RMB3,488.705 million when compared to 31 December 2024. Gearing ratio was -35.0%.* Adjusted profit attributable to owners of the Company include all profit attributable to owners of the Company with the exception of the one-off gain on disposal of subsidiaries. In the first half of 2025, China’s economy continued its momentum of robust development amid ongoing structural challenges. The consumer market became increasingly diversified, with consumers seeking a balance between health and enjoyment, personalization and mainstream choices, and placing greater emphasis on product quality, emotional engagement, and differentiated experiences. Purchasing patterns were characterized by “high frequency, low transaction value”. Meanwhile, instant retail channels expanded, preference-based e-commerce had become an important driver of online traffic, and discount stores and membership stores accelerated their expansion Omni-channel integration and deeper county-level penetration also emerged as key drivers of incremental demand. Against this backdrop, enterprises with sharp market insight and the ability to innovate product offerings to meet health-conscious and scenario-based demands, while achieving deep user engagement and conversion through multi-channel penetration, are vest positioned to adapt efficiently to changing market needs, enhance customer loyalty, and deliver sustainable high-quality growth.In the first half of 2025, the gross profit structure of the instant noodle business continued to improve. The revenue from Instant Noodles Business was RMB13.465 billion, accounting for 33.6% of the Group’s total revenue. During the period, the gross profit margin of Instant Noodles segment expanded by 0.7 percentage points year-on-year to 27.8%, due to product upgrades and price adjustments. As a result of this margin expansion, the profit attributable to shareholders of the Group in the Instant Noodles segment grew 11.9% year-on-year to RMB951 million in the first half of 2025.Amidst rapidly evolving consumption trends and ongoing channel transformation, the Instant Noodles business actively responded to challenges by adhering to a high-quality development philosophy. The Group achieved sustained growth by optimizing its core product categories and innovating its product portfolio. By building a multi-tiered product matrix, the business effectively met consumers' diverse demands for convenient and delicious offerings. In brand marketing, partnerships with leading IPs and a robust celebrity ambassador lineup deepened the brand’s emotional resonance with younger consumers. The business also accelerated its expansion into emerging channels such as snack wholesalers and membership stores, with differentiated products tailored to specific scenarios and market segments. As an industry pioneer, the Group was the first to introduce aerospace technology standards to noodle production, with its “Space-tech Chosen Noodles” setting new benchmarks for quality and consumer trust.The Beverages business adhered to its dual-driver development strategy of “stabilizing growth and optimizing structure”. Segment revenue reached RMB26.359 billion, accounting for 65.7% of the Group’s total revenue. During the period, the gross profit margin for Beverages grew 2.5 percentage points year-on-year to 37.7%, supported by favorable raw material costs and improved management efficiency. Driven by the improvement in gross profit margin year-on-year, the profit attributable to shareholders of the Group in the Beverages segment grew 19.7% year-on-year to RMB1.335 billion in the first half of 2025.Throughout the period, the Group continued to enhance product competitiveness and reinforce its leading position in core categories by ongoing flavor innovation, packaging upgrades and process improvements. At the same time, the Group deepened consumer insights and responded precisely to market demand, leveraging robust R&D capabilities to accelerate product upgrades and innovation. In terms of channel strategy, the Group proactively embraced diversification, establishing a comprehensive omni-channel marketing system to strengthen online and offline integration. Digital transformation continued to be a priority, with accelerated adoption of AI-driven solutions and enterprise-level data platforms, further empowering business decisions and operational efficiency while solidifying the Group’s competitive edge.Mr. Richard Chen, Chief Executive Officer, commented, “Looking into the second half of 2025, we expect government policies to continue supporting consumption and unlocking household spending potential. In this environment, the Group remains committed to implementing the strategic principle of “Consolidate, Reform and Develop”, guided by a long-term perspective and anchored in consumer needs. We will continue to deepen our focus on core businesses, drive operational excellence, and pursue sustainable, high-quality growth.On the product front, we will further optimize our portfolio and increase R&D investment to build a multi-layered, high-quality product lineup, continuously enhancing our product capabilities and competitive differentiation. In brand building, we will implement diversified marketing strategies to strengthen emotional connections with consumers, driving both brand awareness and emotional value.Operationally, we will accelerate digital transformation, prioritising the development of an enterprise-level data platform, deepening AI adoption, and building an intelligent operational system to empower business decision-making. In terms of business quality, we will continue to optimise cost structures, enhance profitability, and ensure steady and high-quality performance.We are dedicated to integrating sustainable development into our business practices, upholding our social responsibilities, and proactively seizing market opportunities to achieve synergistic growth between economic returns and social value. We are committed to delivering premium products to consumers and generous returns to shareholders. We are working with our partners to achieve our vision of a comprehensive food and beverage “National Brand” recognized by the government, trusted by partners, and preferred by consumers.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the“PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.For enquiries, please contact:Investor EnquiriesInvestor Relation Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

OMS Energy and Ministry XR Signed Strategic Memorandum

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - OMS Energy Technologies Inc. ("OMS Energy" or the "Company", stock code: OMSE) and Ministry XR ("Ministry XR"), a leading national institution for AI code governance and technical supervision in Singapore, officially signed a memorandum of understanding on 6 August 2025 to establish an in-depth strategic partnership between two parties. Leveraging AI-driven robotic coding technology and the cutting-edge engineering capabilities possessed by each other, OMS Energy and Ministry XR will jointly promote the intelligent transformation of the traditional energy industry, moving towards a more sustainable development future with high efficiency, low cost and high security.(Left) Mr. How Meng Hock, Chief Executive Officer of OMS Energy and Mr. Andrew Yew, Chief Technology Officer of Ministry XRThis cooperation focuses on the long-term strategic layout of "intelligently reshaping energy", aiming to build a complete ecosystem through three pillars:1.Frontier R&D in AI Robotic CodingOMS Energy and Ministry XR will jointly develop an exclusive AI-driven robotic coding framework tailored for the energy industry, with a focus on breaking through core scenarios such as predictive maintenance, autonomous operation, environmental compliance monitoring, and automation of safety protocols. This technology will significantly reduce human operation errors, eliminate personnel safety risks under different environmental conditions like extreme weather, steep terrain, a space filled with poisonous gas, remote area, etc, improve the uptime of energy infrastructure, and provide technical guarantees for the full-lifecycle inspection and maintenance of critical facilities such as oil and gas pipelines and wellhead systems.2.Commercialization and Large-Scale Market DeploymentTechnology implementation will quickly move from the laboratory to the industrial end: Ministry XR will assist OMS Energy in designing scalable commercialization pathways, including conducting pilot projects, integrating with existing industrial systems, and providing regulatory compliance and certification support. The two parties plan to develop export-grade technologies with global competitiveness, covering the core markets such as Asia-Pacific, the Middle East, and North Africa where OMS Energy currently operate to accelerate the popularization of intelligent solutions in the energy industry.3.Academic and Innovation Ecosystem CollaborationBuilding on OMS Energy's long-term R&D cooperation with institutions such as the A*Star Singapore Institute of Manufacturing Technology (SIMTech), OMS Energy and Ministry XR will jointly establish an "AI-Robotics Innovation Laboratory" with top academic institutions. They will develop professional courses, establish talent delivery channels, promote the direct transformation of scientific research achievements into industrial applications, and form a closed loop of "industry-research-application".Shared Vision: Let Intelligence and ESG Concepts become Industry StandardsMr. How Meng Hock, Chief Executive Officer of OMS Energy, added: "OMS Energy has been deeply engaged in the oil and gas engineering field for nearly 50 years, with 11 manufacturing bases in 6 countries and a professional team of over 600 people. Our core products, OCTG (Oil Country Tubular Goods) and SWS (Surface Wellhead Systems) have sold to over 200 high-quality customers worldwide. This cooperation with Ministry XR will accelerate our business expansion into a 'full-lifecycle pipeline inspection and maintenance service sector in oilfield and urban water supply and wastewater industry', making AI robotics technology the core engine for cost reduction, efficiency improvement, environmental risk elimination and green development in the energy industry. Safety operation is paramount in the oil and gas industry due to the inherent risks associated with the work. AI robotics technology will significantly reduce the risks involved in daily operations in oil and gas projects, especially in extreme climates and harsh geographical environments, and further ensure the sustainability, safety, and efficiency of operations."Mr. Andrew Yew, Chief Technology Officer of Ministry XR stated at the signing ceremony: "As a leading national institution for AI code governance and technical supervision in Singapore, we will participate in the full-lifecycle of OMS Energy projects, providing full-dimensional support from technology selection to strategic implementation. This cooperation is not only a response to the digital transformation of the energy industry but also a proactive layout to lead global energy technology standards."About OMS Energy Technologies Inc.OMS Energy Technologies Inc. is a seasoned engineering and technology enterprise in the upstream oil and gas development sector, specializing in the design, certification, and manufacturing of precision engineering systems. Its core products include OCTG (Oil Country Tubular Goods), SWS (Surface Wellhead Systems), and specialized connectors, while also providing value-added services such as advanced threading processing and pipeline inspection and maintenance. With business covering regions including Asia-Pacific, the Middle East, North Africa, and West Africa, and backed by authoritative certifications such as ISO 9001 and API Q1 as well as stable financial performance, the Company has become a trusted partner in the global energy industry.About Ministry XRMinistry XR is a leading national institution for AI code governance and technical supervision in Singapore, dedicated to promoting the standardized application and industrial implementation of AI and robotics technologies. It has profound industry know-how in fields such as technical standard formulation and evaluation of global cutting-edge technologies, providing strategic guidance and technical support for the digital transformation of key industries.This press release is issued by Messis Global on behalf of OMS Energy Technologies Inc.For investor and media inquiriesEmail: pr@messis-global.com Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

TransNusa Focuses on Organic Growth to Strengthen Network Connectivity in China

TransNusa Increases Flight Options For Two Routes From ManadoPT TransNusa Aviation Mandiri converts two chartered flights from Manado to scheduled commercial flightsTickets sale for Manado to Shanghai and Manado to Shenzhen started on July 29, 2025TransNusa continuously expands international route and starts strengthening Manado base in IndonesiaJAKARTA, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - FOCUSING on organic growth, TransNusa converts two charter flight routes between Manado and Shanghai as well as Manado and Shenzhen to scheduled commercial routes, starting 8 September and 2 October, respectively.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said while the Manado-Shenzhen scheduled commercial flight is direct, the Manado-Shanghai flight plan has a stop-over of between 30 to 35 minutes at the Clark International Airport.“Our main priority and focus is to create new exciting routes for our passengers and offer seamless and fast travels, whether through direct routes or transits routes.” Datuk Francis said, explaining that the Manado-Clark-Shenzhen route is very popular among tourists.“With the launch of these new commercial routes, we hope to provide tourists from Manado and China additional options to travel,” Datuk Francis said, adding that TransNusa will also provide its passengers with options to visit other major tourist destinations from Manado, such as Bali, also known as Indonesia’s Island of Gods.Details of the new RoutesFrom October 2, TransNusa will be operating three flights a week from Manado’s Sam Ratulangi International Airport to Shenzhen Bao’an International Airport. The TransNusa flight, 8B 175, will depart Manado at 21.10pm and arrive at the Shenzhen Bao’an International Airport at 01.00am while TransNusa flight, 8B 176, will depart Shenzhen Bao’an International Airport at 02.00am and arrive in Manado at 05.50am.TransNusa will be operating the Manado-Shenzhen route three times weekly. The Manado-Shenzhen route scheduled commercial flights are on Tuesday, Thursday and Saturday while the Shenzhen-Manado route scheduled commercial flights will be on Wednesday, Friday and Sunday.TransNusa’s scheduled Manado-Shenzhen flight ticket price starts from as low as IDR3.499.000, CNY1.525 and USD226 while it’s schedule flight from Manado to Shanghai ticket price starts from as low as IDR3.988.000, CNY1.688 and USD257. TransNusa tickets are available for purchase at transnusa.co.id and all other main online travel agent platforms worldwide.Meanwhile, the TransNusa flight, 8B 101, from Manado will depart at 14.00pm and arrive at the Clark International Airport at 16.40pm. The flight will depart Clark International Airport at 17.15pm and arrive at the Shanghai Pudong International Airport at 20.55pm. The flight, 8B 102, will depart the Shanghai Pudong International Airport at 23.05pm and arrive at Clark International Airport at 02.30am. The TransNusa 8B 102, will depart Clark International Airport at 03.00am and arrive at Manado’s Sam Ratulangi International Airport at 05.30am.Datuk Bernard said that TransNusa will operate the six hours 50 minutes scheduled commercial flight route 3 times week. TransNusa’s scheduled commercial flight from Manado will depart on Monday, Wednesday, and Friday.For both the newly introduced scheduled commercial flights, Datuk Bernard said TransNusa will be utilizing its C909 jet airliner, which has only 95 seats, to ensure that passengers travel with comfort.Datuk Bernard Francis…TransNusa offers new flight options for its passengersBrief History On TransNusaTransNusa, which had to close business due to the Covid-19 pandemic was injected with new shareholders and management team in 2022. The airline opened its doors for business in October and within six months, in April 2023, launched its first international flight from Jakarta to Kuala Lumpur, Malaysia.After which, under the new leadership of Datuk Francis, and the new management team, the airline successfully launched three more new international routes by the end of 2023. In 2024, the airline continued growing its international and domestic route and at the same time recording historical firsts that also became a significant industry first for the Indonesian aviation industry. Since April 2023, TransNusa has been making headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and diving haven, Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China and provided Indonesians with more pricing and route options to China.TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to be the fastest growing airline in South East Asia.About TransNusaTransNusa Airline, is a Premium Service Carrier. After the take-over, in February 2024, the airline rebranded itself from being a Low-Cost Carrier to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered.TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022. In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently has bases in Jakarta, Bali and Manado.The airline currently flies from Jakarta to Yogyakarta, Bali, Kuala Lumpur, Malaysia, Subang, Malaysia and Guangzhou, China. It also flies from Bali to Jakarta and Manado. TransNusa will be launching its scheduled Bali to Perth route on March 20th and its Bali to Guangzhou route on April13th. TransNusa made history when it became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore, Malaysia and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719 for assistance.TransNusa’s Primary Media Contact:Trina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

Campaign to promote Hong Kong’s advantages in professional services in Vietnam

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) organised a delegation to Hanoi, Vietnam from 5 to 7 August to promote Hong Kong’s professional services and assist Hong Kong professional service providers in exploring business opportunities.As Hong Kong's sixth-largest trading partner and the second largest among ASEAN members, Vietnam has steadily strengthened trade and economic relations with Hong Kong. The delegation aims at further deepening bilateral business ties and introducing Hong Kong's professional services to local businesses there.The delegation, co-led by Patrick Lau, HKTDC Deputy Executive Director, and Rimsky Yuen, Chairman of the HKTDC Professional Services Committee Advisory Committee, comprised 19 Hong Kong professionals from various sectors, including accounting, legal, consulting and corporate services.During the visit, delegate Tim Koo, Director, Normsun Advisory Services Limited, signed a memorandum of understanding (MoU) with the Institute of Trade and Economics of Vietnam, reflecting a commitment by both sides to strengthen cooperation.Meetings with Vietnam’s government bodies, industry associations and large local enterprises – such as the Foreign Investment Agency under Ministry of Finance, Kinh Bac Group, National Innovation Center, The Association of Chartered Certified Accountants Vietnam, The Vietnam Association of Certified Public Accountants, Vietnam Bank’s Association, Vietnam International Arbitration Centre and VMO Holdings – provided a plethora of opportunities for Hong Kong delegates to explore cooperation opportunities with their Vietnamese counterparts. One of the mission highlights, which was the lunch seminar co-hosted by the HKTDC and Vietnam Chamber of Commerce and Industry, successfully promoted Hong Kong’s role as a regional centre for professional services and risk management. Attracting over 120 Vietnamese business representatives and professionals, it encouraged local enterprises to collaborate with Hong Kong service providers when expanding their business or managing risks.At the lunch seminar, Dr Lau said: "This mission is a part of the HKTDC's new Hong Kong Professionals Plus campaign. We hope to tell the stories of Hong Kong through business delegations and visits as well as promote the strengths of Hong Kong's professional services sector, while at the same time assist them to better understand the latest developments in the ASEAN markets and to seize business opportunities."Mr Yuen stated: "As an international financial centre and a regional hub for professional services, Hong Kong possesses top-tier talents offering world-class legal, financial and consulting services. With extensive experience in facilitating cross-border investments and fund-raising over the years, Hong Kong can meet the development needs of Vietnamese enterprises and assist investors from other countries in seizing opportunities in Vietnam."The HKTDC regularly organises business missions across industries. It will continue to conduct outreach activities to promote the advantages of Hong Kong’s professional services, while helping service providers seize more overseas collaboration opportunities.Photo Download: http://bit.ly/4fu1HBjPatrick Lau, HKTDC Deputy Executive Director (third left, front row), and Rimsky Yuen, Chairman of the HKTDC Professional Services Committee Advisory Committee (fourth left, front row), co-led a delegation to Hanoi, Vietnam, comprising 19 delegates from the professional services sectorTim Koo, Director, Normsun Advisory Services Limited (second right) signed a memorandum of understanding (MoU) with the Institute of Trade and Economics of VietnamA highlight of the mission was the lunch seminar co-hosted by the HKTDC and Vietnam Chamber of Commerce and Industry, which attracted over 120 business representatives and professionals from VietnamPatrick Lau, HKTDC Deputy Executive Director, delivered remarks at the lunch seminarRimsky Yuen, Chairman of the HKTDC Professional Services Committee Advisory Committee, spoke at the lunch seminarMedia enquiriesHKTDC’s Communication & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

Shoucheng-Backed Data Center REITs Surge on Market Debut

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - On August 8, the first batch of data center REITs—Nanfang Range Technology Data Center REIT and Nanfang Wanguo Data Center REIT—officially debuted on the Shanghai and Shenzhen stock exchanges, both hitting the daily price limit on their first day of trading, closing at RMB 5.850 and RMB 3.9, respectively. Their strong performance marked the official entry of the REITs market into the "tech new infrastructure" arena and underscored the important role of industrial capital in driving the securitization of computing power infrastructure.As a key investor in both projects, Shoucheng Holdings Limited (0697.HK) has once again found itself in the spotlight. Through its wholly-owned subsidiary, Beijing Shouyuan Xinrong Investment Co., Ltd., and the Beijing Pingzhun Infrastructure Real Estate Investment Fund under its management, Shoucheng Holdings invested in both Nanfang Wanguo Data Center REIT and Nanfang Range Technology Data Center REIT. This represents not only another precise move in the data center sector but also the latest step in Shoucheng’s broader REITs market strategy.Tapping into the “Computing Power Base” to Capture Digital Economy GrowthAccording to public information, the Nanfang Wanguo Data Center REIT is backed by the Guojin Data Cloud Computing Center in Huaqiao, Kunshan, with 4,192 racks; the Nanfang Range Technology Data Center REIT is backed by the A-18 Data Center at Runze (Langfang) International Information Port, located in the Beijing-Tianjin-Hebei National Computing Hub, with 5,897 racks and an occupancy rate exceeding 99%. Both assets are core regional computing power resources, playing a vital role in supporting 5G, artificial intelligence, and big data applications.Industry experts note that the launch of data center REITs marks the first time that public REITs in China have covered the technology innovation infrastructure segment, facilitating more efficient allocation of computing resources and enhancing the capital market’s ability to serve the digital economy.Full-Chain Deployment: Building a Closed-Loop REITs EcosystemShoucheng’s involvement in the REITs market has long gone beyond single investments. Since becoming one of the largest strategic investors in China’s inaugural public REITs in 2021, the company has built a complete ecosystem covering “Pre-REITs industrial fund incubation — platform operations — public REITs exit — strategic placement investment.”Currently, Shoucheng’s REITs fund management scale exceeds RMB 30 billion, with investments spanning transportation hubs, urban renewal, green energy, and data centers. In 2025 alone, the company has invested in the Sunlon REIT and the Huadian REIT, and through the Beijing Pingzhun Infrastructure Real Estate Investment Fund, partnered with China Life Investment and Caixin Life Insurance to launch a RMB 10 billion Pingzhun Infrastructure Fund, further strengthening its position as a leading industrial capital player in the REITs market.Industrial Capital Advantage: Driving Sustainable Market DevelopmentAs an industrial capital investor, Shoucheng Holdings not only provides funding but also leverages its expertise in asset management, operations, and integration of intelligent infrastructure to enhance both the operational efficiency and long-term value of underlying assets. This “capital + operations” dual empowerment model differentiates the company from pure financial investors in the REITs market.Analysts believe that with the ongoing expansion of China’s public REITs market and the acceleration of securitization in emerging infrastructure such as data centers, Shoucheng Holdings is well-positioned to benefit from the convergence of “new tech infrastructure + REITs” and to consolidate its leadership in the sector.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

31 Concept to Debut Patent-Pending Technology at ISS Asia 2025 in Singapore

DUBAI, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - 31 Concept (31C), an emerging leader in network intelligence and cybersecurity innovation, today announced it will unveil its first patent-pending technology at ISS Asia 2025 in Singapore. The breakthrough, developed entirely within the company's 31 Concept Research Lab, marks a major milestone for the startup, which is stepping out of stealth mode after just seven months of intense development.31 Concept's Innovation PatentedThe 31 Concept Research Lab serves as the company's innovation engine, uniting world-class experts in deep packet inspection, AI-driven analytics, cybersecurity, and advanced networking. With decades of combined experience from projects spanning telecom, military, and national infrastructure, the lab's team operates at the intersection of applied research and practical deployment, delivering solutions designed to solve real-world challenges at scale."Our patent-pending technology is the direct result of the unique expertise and relentless drive inside our Research Lab," said Misha Hanin, CEO and Co-Founder of 31C. "We built this in record time without compromising on quality or innovation. This is just the first step in a series of breakthroughs we intend to bring to the market."ISS Asia, recognized as one of the most important professional conferences in the world for intelligence, security, and law enforcement technologies, will provide the global stage for the debut. The event draws leaders from government, telecom, and private industry, making it the perfect venue for 31C's first public presentation."The speed at which the 31 Concept Research Lab turned a concept into a patent-pending reality shows the strength of our people and our process," added Boriss Heismann, CTO of 31C. "This is technology designed to address the most pressing needs in network visibility, security, and performance - and to do it in ways the industry has not seen before."The company's presentation at ISS Asia 2025 will highlight the capabilities of the new platform, detail the patent-pending elements, and outline the roadmap for further innovations currently in development.About 31C31 Concept is a technology company focused on next-generation data intelligence platforms for telecom providers, governments, and regulated industries. Its flagship R&D division, the 31 Concept Research Lab, develops breakthrough technologies in network intelligence, cybersecurity, and AI-driven analytics.Contact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 ConceptRelated Images Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan

HONG KONG, Aug 8, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels.With this label update, the previous requirement in accelerated approval stage to submit full confirmatory trial analysis to demonstrate clinical benefit has been formally removed. Additionally, data demonstrating NEFECON(R)’s efficacy in delaying kidney function decline has been included in the approved product label. IgAN is highly prevalent among Asian populations, with a 56% higher risk of progression to end-stage renal disease compared to other groups and often progresses more rapidly.Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON(R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This further demonstrates NEFECON(R)’s foundational first-line cornerstone treatment for IgAN patients."NEFECON(R) has received full approval in Taiwan, further validating its outstanding clinical value and offering physicians a more solid clinical foundation for treatment decisions.” Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said. “As the first and only fully approved etiological treatment for IgAN, NEFECON(R) has now achieved full approval across Asia. This milestone will benefit a broader patient population by enabling more individuals with IgAN to access this etiological treatment earlier, helping to slow disease progression and improve quality of life. We will continue to expand the accessibility and affordability of NEFECON(R) across Asia, aiming to benefit more IgAN patients and improve their quality of life."The approval is based on the global Phase 3 NefIgArd clinical trial, which showed that compared to placebo, it not only brought about a durable reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR), reducing the decline in kidney function by 50% over a period of 2 years, comprising 9 months of treatment and 15 months of observation, and potentially delaying the progression to dialysis or kidney transplantation by 12.8 years.Additionally, the complete 2-year data of the NefIgArd study further analyzed the potential differences in the response to NEFECON(R) treatment between Asians (n=83) and Caucasians (n=275). The results showed that compared to placebo, treatment with NEFECON(R) for 9 months in both Asians and Caucasians can significantly delay the decline of eGFR, protect kidney function, and bring about a sustained reduction in proteinuria and reduce the risk of microscopic hematuria.NEFECON(R) has been recommended by several authoritative treatment guidelines, including the “KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)”, and the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)". NEFECON(R) was included in China’s National Reimbursement Drug List (NRDL) in November 2024, and the supplemental application for the production expansion of NEFECON(R) has been officially approved by NMPA in August 2025.NEFECON(R) is currently the world’s first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency（MHRA）in the United Kingdom , as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

WRC 2025: Shoucheng Showcases Full Robotics Value Chain

HONG KONG, Aug 8, 2025 - (ACN Newswire via SeaPRwire.com) - From August 8 to 12, 2025, the 8th World Robot Conference (WRC 2025) was held in Beijing. As one of the most influential global events in the robotics sector, this year’s conference achieved record highs in exhibition space, participating companies, and the level of technology showcased. Over 500 companies from around the world gathered to present cutting-edge robotics technologies and real-world applications across industrial, service, special-purpose, and humanoid categories. The event featured significantly more dynamic demonstrations and interactive experiences compared to previous years, reflecting the industry’s accelerated shift from “tech showcases” to “commercial deployment.”For Shoucheng Holdings (0697.HK), a long-term investor in the robotics value chain, WRC 2025 was not only an industry gathering but also an excellent platform to validate its investment strategies and capture future trends. Several Shoucheng portfolio companies took center stage at the event, including Unitree Robotics, a global leader in quadruped and humanoid robots; Galbot, a leader in industrial collaboration robotics; Noetix Robotics, a high-performance joint drive manufacturer; Booster Robotics, a humanoid robot OEM; Galaxea-AI, a full-stack embodied AI company; X Square Robot, an adaptive robotics platform developer; and the Beijing Humanoid Robot Innovation Center, co-founded with Shoucheng’s participation. Together, they represent full value chain coverage from core components to complete machines, and from foundational algorithms to integrated application scenarios.1. From “Showmanship” to “Real Work”: An Industry Turning PointThis year’s WRC marked a notable shift from static displays to high levels of dynamic demonstrations and scenario-based interaction. The focus has moved beyond single metrics such as speed and precision toward capabilities like generalization, high dynamic stability, and dexterous manipulation. This evolution is driven by advances in algorithms and computing power, as well as the maturation of the supply chain. Rapid iteration in critical components such as joints, tactile sensors, and lightweight structures has enabled OEMs to showcase deployable, interactive functional scenarios directly on-site.2. Capital Boom Meets Deployment Surge: Ecosystem Advantages EmergeIn July and August, robotics financing activity surged, with multiple companies less than three years old securing funding rounds exceeding RMB 100 million, and some even preparing for IPOs. This “early-stage companies entering capital markets” trend reflects rising confidence in commercialization. At the same time, hardware-strong companies are expanding into diverse applications ranging from factories to theme parks, sports events, and cultural tourism, while companies with advanced “robot brain” capabilities are accelerating deployment in high-value industrial and logistics sectors.Amid this trend, Shoucheng Holdings leverages its dual advantage of “investment + scenario” to not only identify promising targets in the primary market but also embed portfolio technologies into real-world settings via its smart transportation, industrial park, and infrastructure operations, creating commercial closed loops. For example, portfolio company Wanxun Technology’s autonomous charging robot has already been deployed in Shoucheng-operated parking facilities, transitioning from concept to scaled commercial operations.3. From the Year of Humanoids to the Year of DeliveryAt WRC 2025, humanoid robots shifted from being purely “attention-grabbing” to competing on order volumes and delivery capabilities. Industry investors widely expect 2025–2026 to be the “Year of Delivery,” where companies achieving scaled deployments in real-world scenarios first will gain both valuation and market share advantages. Shoucheng Holdings has also made its strategic stance clear: future competition will be not only about technological leadership but also about value chain collaboration, supply chain resilience, and business model validation.As the industry advances toward scaled applications, Shoucheng Holdings’ ecosystem advantage will become increasingly evident—continuously empowering portfolio companies on the capital side while providing real-world scenarios and commercialization pathways on the operational side, accelerating the robotics industry’s journey from “lab prototypes” to “mass delivery,” and ultimately feeding value back into the capital markets.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. The Company demonstrated robust growth momentum and significant operational optimization during the reporting period, with key financial metrics delivering exceptional performance. Notably, its respiratory intervention product portfolio fueled a substantial revenue surge, marking accelerated commercialization progress.Respiratory Intervention Products Emerge as Core Growth Engine, Highlighting Global Competitive EdgeThe Company recorded revenue of RMB51.1 million for the first half of 2025, a 162.4% increase from RMB19.5 million in the same period of 2024, setting a new historical high. This growth was primarily attributable to the strategic focus on respiratory intervention products entering a harvest phase: The Malignant Stenosis Cryoablation System, approved by China’s National Medical Products Administration (NMPA) in March 2025, and the previously commercialized Cryoadhesion System, experienced rapid sales expansion, becoming the dominant revenue drivers. Additionally, the distribution partnership with Boston Scientific’s China affiliate, BSC International Medical Trading (Shanghai) Co., Ltd. (“BSC”), contributed significant incremental revenue from other respiratory intervention products in mainland China.Of particular significance, the Company’s Asthma Cryoablation System received "Breakthrough Medical Device" designation from the U.S. Food and Drug Administration (FDA) – the first such international recognition for a Chinese enterprise in the respiratory interventional cryotherapy field – laying a foundation for global market expansion.Cryofocus has established a highly competitive respiratory intervention portfolio addressing critical indications, including malignant stenosis, benign stenosis, asthma, chronic obstructive pulmonary disease (COPD), peri-pulmonary nodules, chronic cough, and airway tuberculosis. Among these: The Malignant Stenosis Cryoablation System has been successfully commercialized in China; systems for asthma and COPD are in confirmatory clinical trials with expected approvals in 2026; products for cough, tuberculosis, and peri-pulmonary nodules are in various R&D stages; and the Cryoadhesion System (including disposable and re-sterilizable cryoprobes) is approved and marketed. These innovations mainly stem from Cryofocus’s two core technology platforms: unique liquid nitrogen-based cryoablation technology (utilizing liquid nitrogen as the cryogenic energy source) and advanced flexible catheter technology. This integrated platform enables deep low-temperature treatment, precise control, and minimally invasive intervention, offering superior therapeutic efficacy and safety while creating significant technological barriers for competitors.Platform Value Multiplies as Multi-Segment Strategy Accelerates CommercializationCryofocus’s core value extends beyond its respiratory pipeline, underpinned by its distinction as an innovative cryotherapy platform enterprise. Leveraging its liquid nitrogen and flexible catheter technologies, the Company has successfully expanded into multiple high-potential therapeutic areas:In the vascular intervention segment: The Atrial Fibrillation (AF) Cryoablation System (for atrial fibrillation treatment) was commercialized in China in September 2024. The Cryofocus Renal Denervation (Cryo-RDN) System (for hypertension treatment), granted FDA Breakthrough Device designation, is in confirmatory clinical trials. The Pulmonary Hypertension Cryoablation System is currently in the stage of pre-clinical study. The market space for all these related cardiovascular indications is very huge.In the Natural Orifice Transluminal Endoscopic Surgery (NOTES) segment: The respiratory intervention portfolio, as detailed, is rich and leading. The cancer intervention portfolio includes the commercialized Bladder Cryoablation System; the Gastric Cryoablation System and Esophageal Cryospray System are in clinical trials targeting gastric and esophageal cancer markets.In non-cryotherapy products: Commercialized items such as the Pulmonary Nodule Localization Needle and Endoscopic Clip for Anastomosis, alongside pipeline products like the Atrial Fibrillation Pulsed Field Ablation (PFA) System and Anti-Gastroesophageal Reflux System, create complementary synergies.This "one-platform, multi-therapy" model endows Cryofocus with exceptional adaptability for indication expansion and pipeline sustainability. The Company currently boasts a robust portfolio of 23 products and candidates: 14 cryotherapy and 9 non-cryotherapy items, with 11 already commercialized. Such platform-based diversification is rare among single-therapy medical device firms, highlighting substantial long-term growth potential and risk resilience.Strong Financial Performance and Sustained Growth MomentumBeyond the revenue surge driven by respiratory products, Cryofocus’s interim results signal positive ongoing growth. The Company’s technological advantages further translated into financial resilience. Gross profit reached RMB34.3 million for the first half of 2025, up 124.5% year-on-year, with a solid gross profit margin of 67.1%. Enhanced R&D efficiency led to significantly reduced losses. R&D expenses optimized to RMB17.9 million (down 51.9% year-on-year), while the period loss narrowed 51.4% to RMB27.2 million, demonstrating a clear trend toward profitability. Cash reserves increased 40.1% from year-end 2024 to RMB63.7 million, providing a solid foundation for sustained R&D and market expansion.Revenue diversification and quality improved as high-value self-developed products (e.g., Malignant Stenosis Cryoablation System) launched and scaled, complemented by deepening collaboration with BSC. The significant reduction in R&D expenses reflects improved efficiency and reduced consumable needs as products advance, driven by optimized personnel costs and management enhancements. This establishes a sound framework for balancing innovation intensity with cost control.Furthermore, the Company increased investment in sales network development, with selling and distribution expenses rising 174.4% year-on-year to RMB9.2 million, underscoring proactive resource allocation to build marketing teams and promote newly launched products (e.g., Malignant Stenosis Cryoablation System), laying groundwork for future sales scale expansion.Global Peer Benchmark Highlights Valuation PotentialCryofocus’s technological strength in respiratory interventional cryotherapy, particularly in FDA-designated areas like asthma treatment, positions it competitively against global leaders.Benchmarked against Inspire Medical Systems (INSP) (focusing on OSA neurostimulation, differing in indication but similar in respiratory neuro-intervention): Inspire currently holds a market capitalization of US$2.279 billion and a trailing-twelve-month (TTM) P/E ratio of 44.28x. Cryofocus’s Asthma Cryoablation System similarly targets pulmonary vagal nerves via minimally invasive ablation, with an innovative pathway validated by FDA Breakthrough status. Yet, as a diversified platform innovator with a broad pipeline and multiple commercialized products, Cryofocus’s current Hong Kong market valuation (Inspire’s market cap is 12.8x Cryofocus’s) significantly trails Inspire’s.This substantial valuation gap, while influenced by factors such as differing markets (US vs. HK), stages of development (Inspire being profitable and established in the US market), and a single-product focus versus a platform model, nonetheless clearly underscores the significant upside potential in Cryofocus Medtech's current market valuation relative to its technological capabilities, the breadth of its product pipeline, and its potential for globalization breakthroughs. With the advancement of clinical progress for its respiratory intervention products (particularly the Asthma Cryoablation System COPD Cryospray System Peri-Pulmonary Nodule Cryoablation System), the clarification of overseas registration pathways, and the continued high-speed growth in its revenue scale, a market re-rating of its value represents a high-probability event. The current valuation level presents an attractive window of opportunity for investors bullish on the long-term prospects of the minimally-invasive interventional cryotherapy sector and the value inherent in a platform company model.Looking ahead, Cryofocus maintains a clear strategy: rapidly advance clinical development and commercialization of pipeline products; deepen focus on minimally invasive interventional cryotherapy while expanding the portfolio leveraging its core platforms; continuously invest in underlying and supporting technologies; and selectively expand global operations. The Company is steadily transitioning from R&D-driven to a dual-engine model integrating R&D and commercialization, advancing resolutely toward its vision of becoming a "global platform for minimally invasive interventional cryotherapy medical devices." Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million

HONG KONG, Aug 6, 2025 - (ACN Newswire via SeaPRwire.com) - 5 August, The well-known dual-listed beauty and skincare group in Asia, Natural Beauty Bio-Technology Limited ("Natural Beauty"), together with its subsidiaries (the "Group"; Hong Kong stock code: 00157), today announced its interim results for the six months ended 30 June 2025 (the "Review Period"). The Group's turnover and profit for the Review Period soared by nearly 70% to over HK$260 million and 136% to HK$11 million, respectively. A good number of its core indicators for the period also reached record highs, evidencing the strong development resilience and growth potential of the Group in the beauty and skincare sector.Mainland China, which is the core market of the Group, recorded turnover HK$220 million in the first half of 2025, up 101% year-on-year, and has thus become the main driving force of the Group’s overall performance growth. In terms of channels, the franchise model performed particularly well, contributing turnover of HK$200 million, a 115% increase year-on-year. In the Review Period, 237 new franchise stores were added, a leap of 88%. The rapidly expanding store network has given the segment solid support for turnover growth. Turnover from self-owned channels (including counters) climbed by 112% to HK$13 million, reflecting the success of its refined retail operations. In addition, the turnover of the health supplements segment also grew by 110%, to HK$28 million, a testament to the success of the Group’s “Holistic Health” strategy.Dr. Lei Chien, Chairman and Executive Director of Natural Beauty, said, "The Group's ‘AI Technology, Beauty Industry, Holistic Health’ strategy has brought remarkable results and enabled us to transform our brand. In AI technology development, our strategic partnership with Spain's INDIBA has enabled the integration of their cutting-edge devices with our proprietary formulations, resulting in the co-created White Moonlight product series. By combining advanced international technology with our proprietary skincare solutions, we've transformed the series into a market bestseller - clear validation of this collaborative model's effectiveness.Mr. CHENG Chi-Chung, who has just completed his first year as the Group CEO, has led the team in strategically expanding the beauty ecosystem by introducing an agent-based store expansion and partnership model, driving rapid growth in the franchising channel. He said:” We have established a comprehensive 'Standardized Operations System + End-to-End Support Framework', enabling franchisees to replicate successful models efficiently. This system has facilitated the successful launch of 237 new stores in the first half of this year, all achieving strong business growth.Beyond the dual growth in cosmetics and AI devices, our "Total Wellness" strategy for health supplements delivered outstanding results - generating HK$28 million in revenue with nearly 110% year-on-year growth. The success stems from two key factors: firstly, the products, which closely align with consumers health demand of ‘internal and external nutrition’, are made with premium ingredients sourced globally and technically supported by cross-strait R&D centers apt in delivering high-quality nutritional solutions, and secondly, integrating with ‘Holistic Health’ scenarios, health supplements are promoted alongside skincare services to create closed-loop consumption. That confirms the strong market recognition we enjoy for our comprehensive ‘skincare + health management’ solutions.”Looking ahead, benefiting from consumption rebounding and industry upgrade, the Group will, with its “AI Technology, Beauty Industry, Holistic Health" strategy at the core, push forward in two key directions: continue to integrate industrial chain resources to speed up digital transformation across channels, and use big data to accurately capture demand and build a “demand—R&D—channels” closed-loop system to reinforce the market leadership.Photo caption:Nature Beauty OutletAbout Natural Beauty Bio-Technology Limited (Hong Kong stock code:00157)A China’s leading listed beauty and skincare brand established in 1972, has championed its core philosophy of "Natural Beauty Is True Beauty" for 54 years. Driven by its "AI Technology, Beauty Industry, Holistic Health" integrated strategy, the brand operates a global network of over 2,000 outlets. As a Chinese-origin transnational biotech pioneer, Natural Beauty continues to propel innovation in the cosmetics and skincare sector.Media enquiriesStrategic Financial Relations LimitedMandy GoTel: +852 2864 4812Email: mandy.go@sprg.com.hk Maggie ZhangTel: +852 2114 4903Email: maggie.zhang@sprg.com.hk Website:http://www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-12

31 Concept將在2025年新加坡ISS Asia首度發佈其申請專利的新技術

迪拜，阿聯酋, 2025年8月11日 - (亞太商訊 via SeaPRwire.com) - 作為網絡智能與網絡安全創新領域的新興領導者，31 Concept（簡稱31C）今日宣佈，將在2025年新加坡ISS Asia大會上首次發佈其申請專利的新技術。該突破性成果由公司旗下的31 Concept研究實驗室獨立研發完成，標誌著這家初創企業在僅僅七個月的高強度研發後正式走出隱秘階段，迎來重要里程碑。31 Concept創新成果獲專利31 Concept研究實驗室是公司創新的核心引擎，匯聚了深度封包檢測、人工智慧驅動分析、網路安全及先進網路技術領域的世界級專家。實驗室團隊在電信、軍事及國家基礎設施等專案中累積了數十年的綜合經驗，立足於應用研究與實際部署的交匯點，致力於提供可大規模解決現實挑戰的方案。「我們的申請專利技術，正是源於研究實驗室獨特的專業能力與不懈的進取精神。」31C首席執行官兼聯合創始人 Misha Hanin 表示，「我們在創紀錄的時間內完成了研發，同時毫不妥協於品質與創新。這只是我們計劃推向市場的一系列突破中的第一步。」ISS Asia被公認為全球情報、安全及執法技術領域最重要的專業會議之一，將為此次首發提供全球舞臺。該盛會吸引了來自政府、電信及私營行業的領軍人物，是31C首次公開亮相的理想場所。「31 Concept研究實驗室以極高的速度將一個概念轉化為正在申請專利的現實，充分體現了我們團隊的實力與流程的高效性。」31C首席技術官鮑里斯·海斯曼（Boriss Heismann）補充道，「這項技術旨在解決網路可視性、安全性及性能方面最迫切的需求，而且是以業界前所未有的方式實現的。」在2025年ISS Asia大會上，31C將重點展示這一全新平台的功能，詳細介紹其專利申請中的核心要素，並公佈目前正在研發中的後續創新路線圖。關於31C31 Concept是一家專注於為電信營運商、政府及受監管行業打造新一代數據智能平台的科技公司。其核心研發部門——31 Concept研究實驗室，致力於在網路智能、網路安全及人工智慧驅動分析領域研發突破性技術。聯絡資訊Misha HaninCEOmisha.hanin@31c.io來源: 31 Concept相關圖片 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-12

OMS能源與Ministry XR簽署戰略備忘錄 攜手以AI機器人技術重塑能源行業

香港，2025年8月12日 - (亞太商訊 via SeaPRwire.com) - OMS能源技術公司(「OMS能源」或「公司」，股份代號：OMSE)與新加坡國家人工智能編碼治理與技術監管領軍機構Ministry XR Pte Ltd(以下簡稱「Ministry XR」)於8月6日正式簽署諒解備忘錄，以建立深度戰略合作夥伴關系。OMS能源和Minstry XR將依托各自擁有的AI驅動的機器人編碼技術及卓越的工程能力，共同推動傳統能源行業智能化轉型，邁向更高效低成本且具有高度安全性的可持續發展的未來。(左起) OMS能源首席執行官侯明福及Ministry XR首席技術官Andrew Yew此次合作聚焦「智能重塑能源」的長期戰略佈局，旨在通過三大支柱構建完整生態：1.人工智能機器人編碼前沿研發雙方將聯合開發針對能源行業的專屬AI驅動機器人編碼框架，重點突破預測性維護、自動化運營、環境合規監測及安全規程自動化等核心場景。該技術將大幅減少人為操作誤差、消除極端天氣、陡峭地形、有毒氣體空間、偏遠地區等不同環境條件下的人員安全風險、提升能源基礎設施的正常運行時間，為油氣管道、井口系統等關鍵設施的全生命周期監測及維護提供技術保障。2.商業化與市場規模化部署技術落地將從實驗室快速邁向產業端：Ministry XR部將協助OMS能源設計可擴展的商業化路徑，包括開展試點項目、與現有工業系統整合、提供監管合規與認證支持等。雙方計劃打造具備全球競爭力的出口級技術，覆蓋亞太、中東及北非等OMS能源現有業務所在的核心市場，加速能源行業智能化解決方案的普及。3.學術與創新生態協同依托OMS能源與新加坡製造技術研究院(SIMTech)等機構的長期研發合作基礎，OMS能源與Ministry XR將聯合頂尖學術機構共建「人工智能-機器人創新實驗室」，開發專業課程、搭建人才輸送渠道，推動科研成果直接轉化為產業應用，形成「產研用」閉環。共同願景：讓智能與ESG理念成為行業標準OMS能源首席執行官侯明福先生補充道：「OMS近50年深耕油氣工程領域，在6國擁有11個製造基地及600餘名專業團隊，核心產品OCTG(油井管材)與SWS(地面井口系統)已銷售至全球超200家優質客戶。此次與Ministry XR的合作，將加速我們的業務拓展至『油田及城市水道全生命周期管道監測維護服務』領域，讓AI與機器人技術成為能源行業降本增效、消除環境風險、綠色發展的核心引擎。油氣行業的作業風險高，安全作業至關重要。AI人工智能機器人技術將顯著降低油氣項目日常作業的風險，尤其是在極端氣候和惡劣地理環境下，可進一步確保作業的可持續性、安全性和高效性。」Ministry XR首席技術官Andrew Yew在簽約儀式上表示：「作為新加坡國家人工智能編碼治理與技術監管的領軍機構，我們將全程參與OMS項目生命周期，從技術選型到戰略落地提供全維度支持。此次合作不僅是對能源行業數字化轉型的響應，更是引領全球能源技術標準的主動佈局。」關於OMS能源技術公司OMS能源技術公司是上游油氣開發領域的資深工程技術企業，專註於設計、認證和製造精密工程系統，核心產品包括油井管材(OCTG)、地面井口系統(SWS)及專用連接器等，同時提供高級螺紋加工、管道檢測維護等增值服務。公司業務覆蓋亞太、中東及北非、西非等地區，憑借ISO 9001、API Q1等權威認證及穩健財務表現，成為全球能源行業信賴的合作夥伴。關於Ministry XRMinistry XR是新加坡國家人工智能編碼治理與技術監管的領軍機構，致力於推動AI與機器人技術的規範應用及產業落地，在技術標準製定、全球前沿技術評估等領域具備深厚積累，為關鍵行業數字化轉型提供戰略指導與技術支持。此新聞稿由Messis Global代OMS能源技術公司發布投資者及媒體查詢電郵：pr@messis-global.com Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-12